1. Home
  2. WVE vs VYX Comparison

WVE vs VYX Comparison

Compare WVE & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • VYX
  • Stock Information
  • Founded
  • WVE 2012
  • VYX 1881
  • Country
  • WVE Singapore
  • VYX United States
  • Employees
  • WVE N/A
  • VYX N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • VYX
  • Sector
  • WVE Health Care
  • VYX
  • Exchange
  • WVE Nasdaq
  • VYX Nasdaq
  • Market Cap
  • WVE 2.1B
  • VYX 2.1B
  • IPO Year
  • WVE 2015
  • VYX N/A
  • Fundamental
  • Price
  • WVE $10.99
  • VYX $13.11
  • Analyst Decision
  • WVE Strong Buy
  • VYX Strong Buy
  • Analyst Count
  • WVE 10
  • VYX 7
  • Target Price
  • WVE $21.60
  • VYX $16.33
  • AVG Volume (30 Days)
  • WVE 1.0M
  • VYX 1.3M
  • Earning Date
  • WVE 03-05-2025
  • VYX 02-27-2025
  • Dividend Yield
  • WVE N/A
  • VYX N/A
  • EPS Growth
  • WVE N/A
  • VYX N/A
  • EPS
  • WVE N/A
  • VYX 4.40
  • Revenue
  • WVE $53,610,000.00
  • VYX $3,592,000,000.00
  • Revenue This Year
  • WVE N/A
  • VYX N/A
  • Revenue Next Year
  • WVE $48.58
  • VYX N/A
  • P/E Ratio
  • WVE N/A
  • VYX $3.01
  • Revenue Growth
  • WVE N/A
  • VYX 956.47
  • 52 Week Low
  • WVE $3.50
  • VYX $10.87
  • 52 Week High
  • WVE $16.74
  • VYX $15.98
  • Technical
  • Relative Strength Index (RSI)
  • WVE 34.06
  • VYX 38.96
  • Support Level
  • WVE $10.57
  • VYX $12.74
  • Resistance Level
  • WVE $12.03
  • VYX $13.59
  • Average True Range (ATR)
  • WVE 0.69
  • VYX 0.44
  • MACD
  • WVE -0.17
  • VYX -0.07
  • Stochastic Oscillator
  • WVE 12.54
  • VYX 21.47

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

Share on Social Networks: